Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

Inclusion Criteria:

The main inclusion criteria include, but are not limited to the following:

   - Has a histologically confirmed diagnosis of Ann Arbor Stage III or IV classical
   Hodgkin Lymphoma (cHL). Stage I and II participants may be enrolled, but must have at
   least one National Comprehensive Cancer Network (NCCN) unfavorable risk factor per
   protocol

   - Has measurable 2-fluorodeoxyglucose (FDG)-avid disease based on investigator
   assessment according to Lugano 2014 response criteria

   - Has not received prior radiation therapy, chemotherapy, immunotherapy, or other
   systemic therapy for the treatment of cHL before the first dose of study intervention

   - Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 assessed
   within 7 days before the start of study intervention

Exclusion Criteria:

The main exclusion criteria include, but are not limited to the following:

   - Has confirmed nodular lymphocyte-predominant Hodgkin Lymphoma (HL)

   - Has an uncontrolled intercurrent cardiovascular illness

   - Has received prior therapy with an anti-programmed cell death 1 protein (PD-1),
   anti-programmed cell death ligand 1 protein (PD-L1), or anti- programmed cell death
   ligand 2 protein (PD-L2) agent or with an agent directed to another stimulatory or
   coinhibitory T-cell receptor

   - Has received or is expected to receive a live or live-attenuated vaccine within 30
   days before the first dose of study intervention

   - Is currently participating in or has participated in a study of an investigational
   agent or has used an investigational device within 4 weeks before the first dose of
   study intervention

   - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
   or any other form of immunosuppressive therapy within 7 days prior the first dose of
   study medication

   - Has a known additional malignancy that is progressing or has required active treatment
   within the past 5 years

   - Has radiographically detectable central nervous system metastases and/or carcinomatous
   meningitis

   - Has an active autoimmune disease that has required systemic treatment in past 2 years

   - Has a history of (noninfectious) pneumonitis/interstitial lung disease that required
   steroids or has current pneumonitis/interstitial lung disease

   - Has a history or current evidence of pulmonary fibrosis

   - Has had an allogenic tissue/solid organ transplant